Ikena Oncology, Inc. (NASDAQ:IKNA) Shares Sold by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. lessened its position in shares of Ikena Oncology, Inc. (NASDAQ:IKNA) by 15.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 327,410 shares of the company’s stock after selling 61,338 shares during the quarter. Jacobs Levy Equity Management Inc. owned approximately 0.68% of Ikena Oncology worth $537,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. BNP Paribas Financial Markets acquired a new position in shares of Ikena Oncology during the 4th quarter worth $72,000. Northern Trust Corp grew its holdings in Ikena Oncology by 19.7% in the 4th quarter. Northern Trust Corp now owns 57,565 shares of the company’s stock valued at $94,000 after buying an additional 9,456 shares during the period. JPMorgan Chase & Co. grew its holdings in Ikena Oncology by 18,244.1% in the 4th quarter. JPMorgan Chase & Co. now owns 155,741 shares of the company’s stock valued at $255,000 after buying an additional 154,892 shares during the period. Geode Capital Management LLC increased its position in Ikena Oncology by 21.0% during the 4th quarter. Geode Capital Management LLC now owns 327,962 shares of the company’s stock worth $538,000 after purchasing an additional 56,936 shares in the last quarter. Finally, Peapod Lane Capital LLC acquired a new stake in Ikena Oncology during the 4th quarter worth approximately $833,000. Institutional investors and hedge funds own 75.00% of the company’s stock.

Ikena Oncology Stock Performance

IKNA opened at $1.11 on Friday. The firm has a 50 day moving average price of $1.20 and a 200 day moving average price of $1.44. The company has a market cap of $53.57 million, a PE ratio of -0.90 and a beta of 0.47. Ikena Oncology, Inc. has a 1 year low of $0.97 and a 1 year high of $1.94.

Ikena Oncology (NASDAQ:IKNA) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.03. On average, sell-side analysts predict that Ikena Oncology, Inc. will post -0.91 earnings per share for the current year.

Ikena Oncology Company Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.